ConcertAI has introduced its next-generation CTO 2.0 solution for supporting design and execution of clinical trials.

The new solution, released for clinical trial optimisation, now has three new features.

Discover B2B Marketing That Performs

Combine business intelligence and editorial excellence to reach engaged professionals across 36 leading media platforms.

Find out more

It has expanded data assets through sources that are publicly available for including site and physician level trial information on existing and previous trials.

In partnership with data partners, working operational trial metrics and site profile information it helps highlight trial performance and capabilities of study centres.

The solution also includes social determinants of health information at the physical site as well as the physician/patient levels.

Using the latest information, CTO 2.0 will be able to provide recommendations that automate the selection process of trial sites through a data-driven approach.

GlobalData Strategic Intelligence

US Tariffs are shifting - will you react or anticipate?

Don’t let policy changes catch you off guard. Stay proactive with real-time data and expert analysis.

By GlobalData

Additionally, the SaaS technology will help clinicians and researchers select suitable sites for clinical trials.

This balances potential participants available and previous trial performances at the trial sites to provide the highest likelihood of a study success.

Trial operators will also be able to comply with the FDA mandate that trials should provide meaningful information for the subject outcomes.

CTO 2.0 also ensures research can be conducted at scale using the latest clinical informatics integrations and data standards.

ConcertAI COO Ronan Brown said: “There is a practical and moral imperative to make clinical trials available to all patients, which naturally means expansion of trials into community settings, where over 75% of patients receive their care.

“This aligns with the FDA mandate, and also with the urgent necessity to increase trial diversity. CTO 2.0 is a direct response to these needs.”

Clinical Trials Arena Excellence Awards - Nominations Closed

Nominations are now closed for the Clinical Trials Arena Excellence Awards. A big thanks to all the organisations that entered – your response has been outstanding, showcasing exceptional innovation, leadership, and impact

Excellence in Action
Science 37 has won the Research and Development Award in the Site Innovation category for its FDA inspected Direct-to-Patient Site model, delivering nationwide access, faster enrollment and higher retention. Explore how its virtual-first, in home approach is reshaping trial operations and accelerating time to data-driven decisions..

Discover the Impact